NCT05058417

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sadat City University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, controlled study evaluating empagliflozin tablets administered daily for 8 weeks. The purpose of the study is to evaluate the efficacy and safety of empagliflozin in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using Mayo score for ulcerative colitis activity. Calculation of the score requires patients to undergo colonoscopy at the start of the study and at week 8.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
DRUG	Placebo	participants will receive placebo for 8 consecutive weeks in addition to the standard therapy

Timeline

• Start date: 2021-10-01
• Primary completion: 2025-09-30
• Completion: 2025-12-31
• First posted: 2021-09-27
• Last updated: 2025-07-14

Locations

1 site across 1 country: Egypt